In March 2024 John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of (Artificial Intelligence) AI for their Research and Development (R&D) efforts. This report summarises insights from the workshop.
- Pharmaceutical R&D leaders must understand the potential of AI
- Most AI R&D use cases so far have been for operational or process improvement
- It is still early days for transformative AI R&D use cases
- Multiple challenges in data and people remain
- How to best leverage AI for pharmaceutical R&D
With transparency, realism, and a truly multi-disciplinary and cross-functional mindset, AI has great potential in pharmaceutical R&D. The best is yet to come.
Learn more by downloading your free copy of this report via the button above.
